Lv Xing, Zhao Xiao-Peng, Li Wen-Cong, Xing Nai-Fei, Zong Ke-Qiang, Zhai Yi, Yang Sheng-Lei, Zhang Ji-Yao, Liu Xia
Department of Rehabilitation, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.
College of Pharmacy, Xinjiang Medical University, Ürümqi, China.
Front Nutr. 2025 Aug 21;12:1602034. doi: 10.3389/fnut.2025.1602034. eCollection 2025.
Musculoskeletal diseases (MSDs) are a common group of conditions involving bones, muscles, cartilage, ligaments, and nerves, which significantly impact patients' quality of life and ability to participate in society. Anthocyanins (ACNs), as phytochemicals, possess various pharmacological and biological activities, including anti-apoptotic, antioxidant, anti-inflammatory, and immunosuppressive properties. In recent years, ACNs have shown remarkable potential in improving MSDs. This review article aims to recapitulate the therapeutic potential of ACNs and its mechanism of action in treating MSDs.
Extensive literature was searched and reviewed through online electronic databases (PubMed, Embase, and Web of Science), focusing on analysing the specific roles and molecular mechanisms of ACNs in and studies.
ACNs exert protective effects on MSDs by targeting multiple key signaling pathways, including mitogen-activated protein kinase (MAPK), nuclear factor-kappaB (NF-κB), Wingless-related integration site (Wnt)/β-catenin, phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), adenosyl monophosphate-dependent protein kinase (AMPK), receptor activator of nuclear factor-kappaΒ/receptor activator of nuclear factor-kappaB ligand/osteoprotegerin (RANK/RANKL/OPG) and oxidative stress signaling. In addition, ACNs exhibited anti-inflammatory, anti-apoptotic, and immunosuppressive properties. This article reviews the mechanisms and potential therapeutic applications of ACNs in the prevention and alleviation of MSDs, providing valuable reference points for further research and development of ACNs.
ACNs improve the prevention of MSDs through multiple actions such as antioxidant, anti-inflammatory, immunomodulatory and bone metabolism homeostasis regulation. However, results from and studies still need to be further validated by human clinical trials.
肌肉骨骼疾病(MSDs)是一组常见病症,涉及骨骼、肌肉、软骨、韧带和神经,严重影响患者的生活质量和社会参与能力。花色苷(ACNs)作为植物化学物质,具有多种药理和生物学活性,包括抗凋亡、抗氧化、抗炎和免疫抑制特性。近年来,ACNs在改善MSDs方面显示出显著潜力。这篇综述文章旨在概括ACNs在治疗MSDs中的治疗潜力及其作用机制。
通过在线电子数据库(PubMed、Embase和Web of Science)检索和综述大量文献,重点分析ACNs在[具体研究内容缺失]和[具体研究内容缺失]研究中的具体作用和分子机制。
ACNs通过靶向多种关键信号通路对MSDs发挥保护作用,包括丝裂原活化蛋白激酶(MAPK)、核因子-κB(NF-κB)、无翅型MMTV整合位点家族(Wnt)/β-连环蛋白、磷脂酰肌醇3-激酶/蛋白激酶B(PI3K/Akt)、腺苷酸活化蛋白激酶(AMPK)、核因子-κB受体活化因子/核因子-κB受体活化因子配体/骨保护素(RANK/RANKL/OPG)和氧化应激信号通路。此外,ACNs还表现出抗炎、抗凋亡和免疫抑制特性。本文综述了ACNs在预防和缓解MSDs中的作用机制及潜在治疗应用,为ACNs的进一步研发提供了有价值的参考点。
ACNs通过抗氧化、抗炎、免疫调节和骨代谢稳态调节等多种作用改善MSDs的预防。然而,[具体研究内容缺失]和[具体研究内容缺失]研究的结果仍需通过人体临床试验进一步验证。